NCT06058182Recruiting
RNA as Prognostic Biomarkers in Patients With Acute Coronary Syndrome
Source: ClinicalTrials.gov · Last updated 6 Oct 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Identify circulating protein-coding (mRNAs) or non-coding (ncRNAs) transcripts (ACS\_signature) predictive of ventricular dysfunction in ACS patients undergoing PCI.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 15 Feb 2023
- Start date
- 13 Jul 2020
- Primary completion date
- 30 Jan 2026
- Lead sponsor
- IRCCS Policlinico S. Donato
- Diseases
- Coronary artery disease
- NCT number
- NCT06058182
What you commit to
- Study type: Observational
- Planned participants: 70
- From 13 Jul 2020 to the primary completion date, 30 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous cardiac surgery including coronary artery bypass grafts
- Any contraindication to drug-eluting stent implantation (DES)
Other illness
- Severe valve disease or other conditions requiring cardiac surgery
- Patients with known hypersensitivity or contraindication to any of the following drugs:
- heparin
- aspirin,
- clopidogrel,
- ticlopidine,
- sirolimus,
- everolimus.
- Patients with a documented history of myocardial infarction;
- Patients with advanced ST-segment elevation myocardial infarction (\> 48 h from onset of symptoms/Q waves on electrocardiogram) or undergoing fibrinolysis;
- Patients with malignant neoplasm or systemic disease with quoad vitam prognosis less than 1 year;
- Patients with known active infectious diseases;
Lab values
- Left ventricular ejection fraction (LVEF) \<30% before PCI
- Patients with prior known cardiomyopathy with LVEF \< 40%
Other
- Total chronic occlusions
- Patients in cardiogenic shock
- Patients who are unable to express valid informed consent to the act of enlistment
- Pregnant women
Who the study is looking for
- Age \>18 years
- Patients with ACS (first episode), defined according to the guidelines of the European Society of Cardiology (ESC) 2017
- Indication for percutaneous revascularization treatment
- Informed consent to study enrollment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Policlinico S. Donato, Milan, Italy Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.